# A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

> **NCT07038876** · PHASE2 · RECRUITING · sponsor: **MapLight Therapeutics** · enrollment: 300 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** ML-007C-MA BID
- **DRUG:** ML-007C-MA QD

## Key facts

- **NCT ID:** NCT07038876
- **Lead sponsor:** MapLight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038876, "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07038876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*